X4 Pharmaceuticals (NASDAQ:XFOR) Announces Quarterly Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) released its quarterly earnings data on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03), Zacks reports. The firm had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.07 million.

X4 Pharmaceuticals Stock Down 12.1 %

XFOR opened at $0.26 on Wednesday. The firm has a market cap of $45.05 million, a price-to-earnings ratio of -2.88 and a beta of 0.39. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The firm’s 50-day simple moving average is $0.45 and its 200-day simple moving average is $0.53. X4 Pharmaceuticals has a twelve month low of $0.24 and a twelve month high of $1.60.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a research note on Friday, February 7th.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 76,473 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the transaction, the chief executive officer now owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. The trade was a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Insiders sold 202,663 shares of company stock valued at $91,198 in the last ninety days. Insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

A hedge fund recently raised its stake in X4 Pharmaceuticals stock. Bank of America Corp DE increased its stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,502 shares of the company’s stock after purchasing an additional 22,485 shares during the period. Bank of America Corp DE owned 0.08% of X4 Pharmaceuticals worth $98,000 as of its most recent SEC filing. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.